Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/13/2025

Irritable Bowel Syndrome with Constipation (IBS-C) Treatment Guidelines

Introduction to Tenapanor

  • The British Society of Gastroenterology guidelines recognize tenapanor as an efficacious second-line drug for IBS-C in secondary care, with high-quality evidence supporting its use 1

Mechanism of Action

  • Tenapanor works as a sodium-hydrogen exchange inhibitor, specifically targeting NHE3 (sodium/hydrogen exchanger isoform 3) in the intestine, reducing sodium absorption in the intestine, increasing intestinal fluid volume, accelerating transit time, and softening stool consistency 1

Efficacy and Safety

  • Clinical trials have demonstrated that tenapanor is effective for treating global symptoms of IBS-C, though diarrhea is a common side effect 1
  • The maximum recommended dose of 50 mg twice daily should not be exceeded as there is no evidence supporting higher doses for improved efficacy, and doing so may increase the risk of adverse effects, particularly diarrhea 1